secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K/A
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0000950170-23-047925
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio amends CEO Josh Lehrer's separation agreement with consulting and equity acceleration terms
--------------------------------------------------------------------------------

- Separation agreement dated Sept 7, 2023 provides Tier 1 severance benefits under Executive Severance Plan.
- Lehrer to serve as consultant for up to 12 months or until a Strategic Transaction closes.
- Equity awards continue vesting during consulting; acceleration if Strategic Transaction within 6 months.
- If Strategic Transaction within 3 months, Lehrer receives enhanced benefits as if termination during Change in Control.
- Strategic Transaction defined broadly: merger, sale, reverse merger, or Sale Event under 2021 Stock Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/0000950170-23-047925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/grph-20230818.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer